| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5700199 | Clinical Oncology | 2006 | 7 Pages |
Abstract
Web randomisation was successful; however, the high ineligibility rate precludes a full-scale dexamethasone dose trial in Australia. Choice of measure of ambulation has potentially significant effects on outcomes and implications for the design of any future MSCC trials. Referral delays are of concern.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
P.H. Graham, A. Capp, G. Delaney, G. Goozee, B. Hickey, S. Turner, L. Browne, C. Milross, A. Wirth,